Noxopharm Limited (ASX:NOX)
Australia · Delayed Price · Currency is AUD 0.0650
-0.0020 (-2.99%)
Sep 18, 2026, 1:54 PM AEST
Noxopharm Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 0.29 | 1.55 | 2.32 | 3.01 | 14.01 |
Cash & Short-Term Investments | 0.29 | 1.55 | 2.32 | 3.01 | 14.01 |
Cash Growth | -81.11% | -33.01% | -22.89% | -78.53% | -47.71% |
Accounts Receivable | - | - | - | - | 0.01 |
Other Receivables | 1.51 | 2.95 | 2.4 | 6.08 | 5.21 |
Receivables | 1.51 | 2.95 | 2.4 | 6.08 | 5.21 |
Inventory | - | - | - | - | 1.15 |
Prepaid Expenses | 0.03 | 0.08 | 0.04 | 0.07 | 0.46 |
Total Current Assets | 1.83 | 4.58 | 4.77 | 9.16 | 20.83 |
Property, Plant & Equipment | 0 | 0 | 0.01 | 0.01 | 0.22 |
Long-Term Investments | - | - | 2.01 | 0.96 | 5.42 |
Other Long-Term Assets | - | - | - | - | 0.12 |
Total Assets | 1.84 | 4.58 | 6.78 | 10.13 | 26.59 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 0.14 | 0.45 | 0.65 | 0.45 | 0.81 |
Accrued Expenses | 0.7 | 0.93 | 0.51 | 0.41 | 1.14 |
Short-Term Debt | 4.57 | 2.48 | - | - | - |
Current Portion of Leases | - | - | - | - | 0.16 |
Other Current Liabilities | 0.04 | 0.01 | 0.08 | 0.1 | 0.17 |
Total Current Liabilities | 5.46 | 3.87 | 1.25 | 0.96 | 2.28 |
Pension & Post-Retirement Benefits | 0.02 | 0.02 | 0.04 | 0.09 | 0.19 |
Total Liabilities | 5.48 | 3.89 | 1.29 | 1.06 | 2.48 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 74.64 | 74.64 | 74.64 | 74.64 | 74.64 |
Retained Earnings | -78.48 | -74.65 | -70.07 | -72.06 | -58.8 |
Comprehensive Income & Other | 0.2 | 0.7 | 0.93 | 6.5 | 8.29 |
Total Common Equity | -3.65 | 0.69 | 5.5 | 9.07 | 24.12 |
Shareholders' Equity | -3.65 | 0.69 | 5.5 | 9.07 | 24.12 |
Total Liabilities & Equity | 1.84 | 4.58 | 6.78 | 10.13 | 26.59 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 4.57 | 2.48 | - | - | 0.16 |
Net Cash (Debt) | -4.28 | -0.92 | 2.32 | 3.01 | 13.85 |
Net Cash Growth | - | - | -22.89% | -78.28% | -47.63% |
Net Cash Per Share | -0.01 | -0.00 | 0.01 | 0.01 | 0.05 |
Filing Date Shares Outstanding | 301.88 | 292.24 | 292.24 | 292.24 | 292.24 |
Total Common Shares Outstanding | 301.88 | 292.24 | 292.24 | 292.24 | 292.24 |
Working Capital | -3.63 | 0.71 | 3.52 | 8.2 | 18.55 |
Book Value Per Share | -0.01 | 0.00 | 0.02 | 0.03 | 0.08 |
Tangible Book Value | -3.65 | 0.69 | 5.5 | 9.07 | 24.12 |
Tangible Book Value Per Share | -0.01 | 0.00 | 0.02 | 0.03 | 0.08 |